| Sanofi-Aventis (Suisse) SA - Efluelda TIV 0.5 mL, suspension injectable en seringue pré-remplie | | 69863 | | 03 | | Efluelda TIV 0.5 mL | | suspension injectable en seringue pré-remplie | | J07BB02 | | Influenza, Inactivated, Split Virus Or Surface Antigen | | 13.08.2026 | | |
| | Composition | | haemagglutininum influenzae A (H1N1) (Virus souche A/Missouri/11/2025 (H1N1)-like: reassortant virus IVR-278 derived from A/Switzerland/6849/2025) 60 µg, haemagglutininum influenzae A (H3N2) (Virus souche A/Darwin/1454/2025 (H3N2)-like: reassortant virus SAN-049A derived from A/Michigan/105/2025) 60 µg, haemagglutininum influenzae B (Virus souche B/Tokyo/EIS13-175/2025-like: derived from B/Tokyo/EIS-175/2025 (Victoria lineage), wild type) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.96 mg. | | Packungsbestandteile | | | | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 005 | | | | B | | No | | 006 | 10 | | | B | | Yes |
|
|
